Symbols / ALDX Stock $1.55 -3.13% Aldeyra Therapeutics, Inc.
ALDX (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Ratings
Current target
$1.55
Low
$2.00
High
$13.00
Mean
$7.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-18 | down | HC Wainwright & Co. | Buy → Neutral | $2 |
| 2025-11-10 | reit | BTIG | Buy → Buy | $9 |
| 2025-05-19 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-04-07 | main | BTIG | Buy → Buy | $9 |
| 2025-04-04 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-03-03 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-08-09 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-08-02 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-05-06 | reit | Oppenheimer | Outperform → Outperform | $10 |
| 2024-05-06 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-04-03 | up | Oppenheimer | Perform → Outperform | $10 |
| 2023-10-17 | main | Citigroup | Buy → Buy | $8 |
| 2023-10-17 | down | Oppenheimer | Outperform → Perform | — |
| 2023-08-09 | reit | Oppenheimer | Outperform → Outperform | $14 |
| 2023-06-30 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2023-06-22 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2023-06-16 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2023-06-01 | main | Citigroup | Buy → Buy | $25 |
| 2023-05-05 | reit | HC Wainwright & Co. | — → Buy | $15 |
| 2023-03-10 | main | Citigroup | Buy → Buy | $28 |
- $ALDX stock is up 13% today. Here's what we see in our data. - Quiver Quantitative Fri, 10 Apr 2026 07
- ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Reiterated Misleading Claims: SueWallSt - PR Newswire hu, 23 Apr 2026 13
- Aldeyra Therapeutics Announces Upcoming Board Member Departure - The Globe and Mail ue, 21 Apr 2026 21
- Aldeyra (ALDX) Stock: What Investors Should Know (-1.67%) 2026-04-20 - Community Momentum Stocks - Cổng thông tin điện tử Tỉnh Sơn La Mon, 20 Apr 2026 16
- Aldeyra Therapeutics (NASDAQ: ALDX) director to exit after 2026 vote - Stock Titan Mon, 20 Apr 2026 21
- ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud - GlobeNewswire Mon, 20 Apr 2026 20
- Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year? - Yahoo Finance hu, 26 Feb 2026 08
- ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Executive Allegedly Approved Misleading Disclosures: Levi & Korsinsky - Sahm Wed, 22 Apr 2026 07
- Aldeyra Therapeutics (ALDX) Is Down 75.2% After FDA Rebuffs Dry Eye Drug Efficacy Data - Has The Bull Case Changed? - simplywall.st Wed, 18 Mar 2026 07
- Aldeyra (NASDAQ: ALDX) grants CEO 1.88M options and bonus units - Stock Titan ue, 31 Mar 2026 07
- Does Aldeyra Therapeutics (ALDX) Have the Potential to Rally 79.28% as Wall Street Analysts Expect? - Yahoo Finance hu, 19 Feb 2026 08
- ALDX (Aldeyra Therapeutics Inc.) reports narrower Q4 2025 loss than forecast, topping consensus EPS estimates by 60 percent. - Shared Trade Alerts - Cổng thông tin điện tử Tỉnh Sơn La Wed, 22 Apr 2026 23
- Dry eye drug’s fast-acting promise stalls as FDA questions trial results - Stock Titan ue, 17 Mar 2026 07
- ADLX Stockholders Have Rights – If You Lost Money Investing - GlobeNewswire Mon, 20 Apr 2026 20
- ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Reiterated Misleading Claims: SueWallSt - Barchart.com hu, 23 Apr 2026 13
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
35.27
-41.34%
|
60.12
+40.48%
|
42.79
-31.73%
|
62.68
|
| Research And Development |
|
25.66
-46.78%
|
48.22
+63.70%
|
29.46
-37.73%
|
47.31
|
| Selling General And Administration |
|
9.60
-19.26%
|
11.89
-10.82%
|
13.34
-13.26%
|
15.37
|
| General And Administrative Expense |
|
9.60
-19.26%
|
11.89
-10.82%
|
13.34
-13.26%
|
15.37
|
| Other Gand A |
|
9.60
-19.26%
|
11.89
-10.82%
|
13.34
-13.26%
|
15.37
|
| Total Expenses |
|
35.27
-41.34%
|
60.12
+40.48%
|
42.79
-31.73%
|
62.68
|
| Operating Income |
|
-35.27
+41.34%
|
-60.12
-40.48%
|
-42.79
+31.73%
|
-62.68
|
| Total Operating Income As Reported |
|
-35.27
+41.34%
|
-60.12
-40.48%
|
-42.79
+31.73%
|
-62.68
|
| EBITDA |
|
-31.69
+40.96%
|
-53.68
-52.45%
|
-35.21
+41.39%
|
-60.07
|
| Normalized EBITDA |
|
-31.69
+40.96%
|
-53.68
-52.45%
|
-35.21
+41.39%
|
-60.07
|
| Reconciled Depreciation |
|
0.25
+0.95%
|
0.25
-5.01%
|
0.26
+1.57%
|
0.26
|
| EBIT |
|
-31.94
+40.77%
|
-53.93
-52.03%
|
-35.47
+41.21%
|
-60.33
|
| Total Unusual Items |
|
—
|
—
|
—
|
—
|
| Total Unusual Items Excluding Goodwill |
|
—
|
—
|
—
|
—
|
| Special Income Charges |
|
—
|
—
|
—
|
—
|
| Net Income |
|
-33.85
+39.40%
|
-55.85
-48.77%
|
-37.54
+39.47%
|
-62.02
|
| Pretax Income |
|
-33.85
+39.40%
|
-55.85
-48.77%
|
-37.54
+39.47%
|
-62.02
|
| Net Non Operating Interest Income Expense |
|
1.42
-66.74%
|
4.27
-18.78%
|
5.25
+701.34%
|
0.66
|
| Interest Expense Non Operating |
|
1.91
-1.09%
|
1.93
-7.01%
|
2.07
+22.27%
|
1.69
|
| Net Interest Income |
|
1.42
-66.74%
|
4.27
-18.78%
|
5.25
+701.34%
|
0.66
|
| Interest Expense |
|
1.91
-1.09%
|
1.93
-7.01%
|
2.07
+22.27%
|
1.69
|
| Interest Income Non Operating |
|
3.32
-46.32%
|
6.19
-15.45%
|
7.32
+211.69%
|
2.35
|
| Interest Income |
|
3.32
-46.32%
|
6.19
-15.45%
|
7.32
+211.69%
|
2.35
|
| Tax Provision |
|
—
|
—
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-33.85
+39.40%
|
-55.85
-48.77%
|
-37.54
+39.47%
|
-62.02
|
| Net Income From Continuing Operation Net Minority Interest |
|
-33.85
+39.40%
|
-55.85
-48.77%
|
-37.54
+39.47%
|
-62.02
|
| Net Income From Continuing And Discontinued Operation |
|
-33.85
+39.40%
|
-55.85
-48.77%
|
-37.54
+39.47%
|
-62.02
|
| Net Income Continuous Operations |
|
-33.85
+39.40%
|
-55.85
-48.77%
|
-37.54
+39.47%
|
-62.02
|
| Normalized Income |
|
-33.85
+39.40%
|
-55.85
-48.77%
|
-37.54
+39.47%
|
-62.02
|
| Net Income Common Stockholders |
|
-33.85
+39.40%
|
-55.85
-48.77%
|
-37.54
+39.47%
|
-62.02
|
| Diluted EPS |
|
-0.56
+40.43%
|
-0.94
-46.87%
|
-0.64
+39.62%
|
-1.06
|
| Basic EPS |
|
-0.56
+40.43%
|
-0.94
-46.87%
|
-0.64
+39.62%
|
-1.06
|
| Basic Average Shares |
|
60.06
+0.96%
|
59.48
+0.92%
|
58.94
+0.92%
|
58.41
|
| Diluted Average Shares |
|
60.06
+0.96%
|
59.48
+0.92%
|
58.94
+0.92%
|
58.41
|
| Diluted NI Availto Com Stockholders |
|
-33.85
+39.40%
|
-55.85
-48.77%
|
-37.54
+39.47%
|
-62.02
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
72.06
-31.11%
|
104.61
-29.48%
|
148.33
-18.18%
|
181.29
|
| Current Assets |
|
71.78
-31.03%
|
104.07
-29.59%
|
147.81
-18.35%
|
181.02
|
| Cash Cash Equivalents And Short Term Investments |
|
70.04
-30.76%
|
101.15
-29.18%
|
142.82
-18.06%
|
174.30
|
| Cash And Cash Equivalents |
|
70.04
+28.45%
|
54.53
-61.82%
|
142.82
-1.11%
|
144.42
|
| Cash Equivalents |
|
40.47
+31.44%
|
30.79
+115.15%
|
14.31
+54.43%
|
9.27
|
| Cash Financial |
|
29.57
+24.58%
|
23.73
-81.53%
|
128.51
-4.91%
|
135.15
|
| Other Short Term Investments |
|
0.00
-100.00%
|
46.62
|
0.00
-100.00%
|
29.88
|
| Receivables |
|
—
|
—
|
0.00
-100.00%
|
3.24
|
| Other Receivables |
|
—
|
—
|
—
|
3.24
|
| Prepaid Assets |
|
0.41
-0.22%
|
0.41
+19.89%
|
0.34
-21.25%
|
0.43
|
| Current Deferred Assets |
|
1.04
-52.84%
|
2.21
-50.45%
|
4.46
+71.34%
|
2.61
|
| Other Current Assets |
|
0.29
-3.06%
|
0.30
+64.43%
|
0.18
-58.63%
|
0.44
|
| Total Non Current Assets |
|
0.28
-48.36%
|
0.53
+3.41%
|
0.52
+92.36%
|
0.27
|
| Net PPE |
|
0.28
+3.34%
|
0.27
-48.32%
|
0.52
+92.36%
|
0.27
|
| Gross PPE |
|
0.28
+3.34%
|
0.27
-48.32%
|
0.52
+92.36%
|
0.27
|
| Other Properties |
|
0.28
+3.34%
|
0.27
-48.32%
|
0.52
+92.36%
|
0.27
|
| Non Current Deferred Assets |
|
0.00
-100.00%
|
0.27
|
0.00
|
—
|
| Total Liabilities Net Minority Interest |
|
27.81
-17.24%
|
33.60
+17.77%
|
28.53
-5.78%
|
30.28
|
| Current Liabilities |
|
27.81
+49.50%
|
18.60
-16.43%
|
22.26
+44.92%
|
15.36
|
| Payables And Accrued Expenses |
|
2.01
-74.82%
|
7.97
+110.36%
|
3.79
-63.51%
|
10.38
|
| Payables |
|
0.16
-12.19%
|
0.18
-86.51%
|
1.34
+901.35%
|
0.13
|
| Accounts Payable |
|
0.16
-12.19%
|
0.18
-86.51%
|
1.34
+901.35%
|
0.13
|
| Current Accrued Expenses |
|
1.85
-76.27%
|
7.79
+217.95%
|
2.45
-76.10%
|
10.24
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
4.27
-1.39%
|
4.33
+40.33%
|
3.09
-19.20%
|
3.82
|
| Current Debt And Capital Lease Obligation |
|
15.53
+5025.42%
|
0.30
-98.03%
|
15.39
+1225.18%
|
1.16
|
| Current Debt |
|
15.25
+48509.05%
|
0.03
-99.79%
|
15.15
+1561.24%
|
0.91
|
| Other Current Borrowings |
|
15.25
+48509.05%
|
0.03
-99.79%
|
15.15
+1561.24%
|
0.91
|
| Current Capital Lease Obligation |
|
0.28
+3.28%
|
0.27
+13.57%
|
0.24
-4.04%
|
0.25
|
| Current Deferred Liabilities |
|
6.00
+0.00%
|
6.00
|
0.00
|
—
|
| Current Deferred Revenue |
|
6.00
+0.00%
|
6.00
|
0.00
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
-100.00%
|
15.00
+139.17%
|
6.27
-57.97%
|
14.92
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
15.00
+5422.20%
|
0.27
-98.18%
|
14.92
|
| Long Term Debt |
|
—
|
15.00
|
—
|
14.92
|
| Long Term Capital Lease Obligation |
|
—
|
0.00
-100.00%
|
0.27
|
0.00
|
| Non Current Deferred Liabilities |
|
—
|
0.00
-100.00%
|
6.00
|
0.00
|
| Non Current Deferred Revenue |
|
—
|
0.00
-100.00%
|
6.00
|
0.00
|
| Stockholders Equity |
|
44.25
-37.68%
|
71.00
-40.73%
|
119.80
-20.67%
|
151.01
|
| Common Stock Equity |
|
44.25
-37.68%
|
71.00
-40.73%
|
119.80
-20.67%
|
151.01
|
| Capital Stock |
|
0.06
+0.86%
|
0.06
+0.76%
|
0.06
+1.09%
|
0.06
|
| Common Stock |
|
0.06
+0.86%
|
0.06
+0.76%
|
0.06
+1.09%
|
0.06
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
60.16
+0.86%
|
59.65
+0.76%
|
59.20
+1.09%
|
58.56
|
| Ordinary Shares Number |
|
60.16
+0.86%
|
59.65
+0.76%
|
59.20
+1.09%
|
58.56
|
| Additional Paid In Capital |
|
528.15
+1.37%
|
521.02
+1.37%
|
513.99
+1.23%
|
507.77
|
| Retained Earnings |
|
-483.96
-7.52%
|
-450.11
-14.17%
|
-394.26
-10.52%
|
-356.72
|
| Gains Losses Not Affecting Retained Earnings |
|
0.00
-100.00%
|
0.04
|
0.00
+100.00%
|
-0.10
|
| Other Equity Adjustments |
|
—
|
0.04
|
—
|
-0.10
|
| Total Equity Gross Minority Interest |
|
44.25
-37.68%
|
71.00
-40.73%
|
119.80
-20.67%
|
151.01
|
| Total Capitalization |
|
44.25
-48.55%
|
86.00
-28.21%
|
119.80
-27.80%
|
165.93
|
| Working Capital |
|
43.97
-48.55%
|
85.47
-31.92%
|
125.55
-24.21%
|
165.66
|
| Invested Capital |
|
59.50
-30.84%
|
86.04
-36.24%
|
134.94
-19.12%
|
166.84
|
| Total Debt |
|
15.53
+1.48%
|
15.30
-2.26%
|
15.66
-2.65%
|
16.08
|
| Capital Lease Obligations |
|
0.28
+3.28%
|
0.27
-46.82%
|
0.51
+104.93%
|
0.25
|
| Net Tangible Assets |
|
44.25
-37.68%
|
71.00
-40.73%
|
119.80
-20.67%
|
151.01
|
| Tangible Book Value |
|
44.25
-37.68%
|
71.00
-40.73%
|
119.80
-20.67%
|
151.01
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-33.35
+22.83%
|
-43.21
-42.48%
|
-30.33
+46.46%
|
-56.64
|
| Cash Flow From Continuing Operating Activities |
|
-33.35
+22.83%
|
-43.21
-42.48%
|
-30.33
+46.46%
|
-56.64
|
| Net Income From Continuing Operations |
|
-33.85
+39.40%
|
-55.85
-48.77%
|
-37.54
+39.47%
|
-62.02
|
| Depreciation Amortization Depletion |
|
0.25
+0.95%
|
0.25
-5.01%
|
0.26
+1.57%
|
0.26
|
| Depreciation And Amortization |
|
0.25
+0.95%
|
0.25
-5.01%
|
0.26
+1.57%
|
0.26
|
| Other Non Cash Items |
|
0.22
+23.08%
|
0.18
-49.94%
|
0.35
+6.96%
|
0.33
|
| Stock Based Compensation |
|
6.09
-23.60%
|
7.97
+38.60%
|
5.75
-30.60%
|
8.29
|
| Asset Impairment Charge |
|
0.27
|
0.00
|
—
|
—
|
| Deferred Tax |
|
—
|
—
|
—
|
—
|
| Deferred Income Tax |
|
—
|
—
|
—
|
—
|
| Change In Working Capital |
|
-5.18
-187.57%
|
5.91
+586.64%
|
0.86
+125.00%
|
-3.44
|
| Change In Prepaid Assets |
|
1.18
-42.94%
|
2.07
+19.09%
|
1.73
+146.14%
|
-3.76
|
| Change In Payables And Accrued Expense |
|
-6.36
-265.25%
|
3.85
+155.97%
|
-6.87
-2273.11%
|
0.32
|
| Change In Accrued Expense |
|
-6.34
-226.59%
|
5.00
+161.95%
|
-8.08
-771.84%
|
1.20
|
| Change In Payable |
|
-0.02
+98.10%
|
-1.16
-196.11%
|
1.20
+235.93%
|
-0.89
|
| Change In Account Payable |
|
-0.02
+98.10%
|
-1.16
-196.11%
|
1.20
+235.93%
|
-0.89
|
| Change In Other Working Capital |
|
—
|
—
|
6.00
|
—
|
| Investing Cash Flow |
|
47.74
+206.28%
|
-44.92
-249.72%
|
30.00
+200.15%
|
-29.95
|
| Cash Flow From Continuing Investing Activities |
|
47.74
+206.28%
|
-44.92
-249.72%
|
30.00
+200.15%
|
-29.95
|
| Net PPE Purchase And Sale |
|
—
|
—
|
0.00
+100.00%
|
-0.02
|
| Purchase Of PPE |
|
—
|
—
|
0.00
+100.00%
|
-0.02
|
| Capital Expenditure |
|
—
|
—
|
—
|
-0.02
|
| Net Investment Purchase And Sale |
|
47.74
+206.28%
|
-44.92
-249.72%
|
30.00
+200.21%
|
-29.94
|
| Purchase Of Investment |
|
-40.26
+58.45%
|
-96.92
|
0.00
+100.00%
|
-92.94
|
| Sale Of Investment |
|
88.00
+69.23%
|
52.00
+73.33%
|
30.00
-52.38%
|
63.00
|
| Financing Cash Flow |
|
1.12
+755.43%
|
-0.17
+86.50%
|
-1.27
-204.11%
|
1.22
|
| Cash Flow From Continuing Financing Activities |
|
1.12
+755.43%
|
-0.17
+86.50%
|
-1.27
-204.11%
|
1.22
|
| Net Issuance Payments Of Debt |
|
0.00
+100.00%
|
-0.29
+71.94%
|
-1.04
|
0.00
|
| Repayment Of Debt |
|
0.00
+100.00%
|
-0.29
+71.94%
|
-1.04
|
0.00
|
| Long Term Debt Payments |
|
0.00
+100.00%
|
-0.29
+71.94%
|
-1.04
|
0.00
|
| Net Long Term Debt Issuance |
|
0.00
+100.00%
|
-0.29
+71.94%
|
-1.04
|
0.00
|
| Net Common Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Proceeds From Stock Option Exercised |
|
1.12
+189.32%
|
0.39
+27.23%
|
0.31
-74.98%
|
1.22
|
| Net Other Financing Charges |
|
—
|
-0.27
+49.85%
|
-0.53
|
—
|
| Changes In Cash |
|
15.51
+117.57%
|
-88.30
-5431.12%
|
-1.60
+98.13%
|
-85.37
|
| Beginning Cash Position |
|
54.53
-61.82%
|
142.82
-1.11%
|
144.42
-37.15%
|
229.79
|
| End Cash Position |
|
70.04
+28.45%
|
54.53
-61.82%
|
142.82
-1.11%
|
144.42
|
| Free Cash Flow |
|
-33.35
+22.83%
|
-43.21
-42.48%
|
-30.33
+46.47%
|
-56.65
|
| Interest Paid Supplemental Data |
|
1.69
-3.74%
|
1.75
+3.03%
|
1.70
+27.17%
|
1.34
|
| Amortization Of Securities |
|
-1.15
+31.21%
|
-1.67
-11390.74%
|
-0.01
+69.22%
|
-0.05
|
| Common Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Issuance Of Capital Stock |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-20 View
- 8-K2026-04-01 View
- 42026-03-31 View
- 42026-03-20 View
- 42026-03-19 View
- 8-K2026-03-17 View
- 10-K2026-02-27 View
- 8-K2025-12-31 View
- 8-K2025-12-16 View
- 8-K2025-11-13 View
- 10-Q2025-11-05 View
- 8-K2025-10-28 View
- 8-K2025-08-19 View
- 42025-08-15 View
- 42025-08-13 View
- 10-Q2025-08-07 View
- 8-K2025-07-17 View
- 8-K2025-06-26 View
- 8-K2025-06-17 View
- 42025-06-12 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|